A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of EIDD-2801 in hospitalized patients with COVID-19
Latest Information Update: 13 Jul 2020
At a glance
- Drugs Molnupiravir (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 07 Jul 2020 According to a Ridgeback Biotherapeutics media release, it has started of enrollment in a Phase 2 trial of potential COVID-19 treatment EIDD-2801.Trial to be Conducted with the University of Liverpool, Liverpool School of Tropical Medicine & Southampton Clinical Trials Unit.
- 07 Jul 2020 Status changed from planning to recruiting, according to a Ridgeback Biotherapeutics media release.
- 25 Jun 2020 New trial record